Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
69.78 USD | -1.13% | +2.13% | -2.00% |
Evolution of the average Target Price on Ligand Pharmaceuticals Incorporated
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Ligand Pharmaceuticals Incorporated
Barclays | |
Roth Capital Partners | |
HC Wainwright | |
CJS Securities | |
Stephens Inc. | |
Benchmark Capital | |
Craig-Hallum |
EPS Revisions
- Stock Market
- Equities
- LGND Stock
- Consensus Ligand Pharmaceuticals Incorporated